CJC1295 with DAC Research Overview
CJC1295 with DAC Magnus Pharmaceuticals is a synthetic growth hormone releasing hormone (GHRH) analogue peptide designed for in-vitro laboratory research applications. This modified GHRH compound incorporates a Drug Affinity Complex (DAC) component that significantly extends its biological half-life compared to standard CJC1295 formulations. The peptide represents an advanced research tool for investigating growth hormone secretion pathways and pituitary function in controlled laboratory environments. Magnus Pharmaceuticals has developed this compound to meet the stringent requirements of research institutions studying hormone regulation mechanisms. The DAC modification allows researchers to examine extended-duration hormone release patterns, making it particularly valuable for comprehensive endocrinological studies. Research teams at Stroid UK Shop can access this compound for detailed growth hormone axis investigations.
Growth Hormone Research Applications
Laboratory studies examine CJC1295 with DAC for its interaction with GHRH receptors and subsequent growth hormone release mechanisms. The compound demonstrates prolonged activity profiles in preclinical models, enabling researchers to study sustained hormone secretion patterns over extended observation periods. In-vitro studies investigate how the DAC component affects peptide stability and receptor binding affinity. Research applications include examining pituitary cell responses, hormone cascade mechanisms, and cellular signalling pathways associated with growth hormone regulation. The compound’s modified structure provides researchers with opportunities to study how peptide modifications influence biological activity and duration. Scientists investigating CJC-1295 peptides often compare DAC and non-DAC variants to understand structural-functional relationships. Research protocols examine dose-response relationships and temporal activity patterns in controlled laboratory settings. Advanced studies investigate the compound’s effects on cellular metabolism and growth factor expression in various tissue models. Comparative research with other selective androgen receptor modulators helps elucidate hormone interaction mechanisms. The compound serves as a valuable tool for studying growth hormone physiology and developing new research methodologies within the broader field of peptide research.
Laboratory Specifications
| Parameter | Specification |
|---|---|
| Compound Class | GHRH Analogue Peptide with DAC |
| Molecular Formula | Verify with supplier |
| Molecular Weight | Verify with supplier |
| CAS Number | Verify with supplier |
| Purity | Research grade |
| Form | Lyophilised powder |
| Storage | -20°C, protect from light |
| Solubility | Water soluble when reconstituted |
Research Use Compliance
CJC1295 with DAC Magnus Pharmaceuticals is manufactured exclusively for in-vitro laboratory research purposes and is not intended for human consumption, therapeutic use, or any application outside of controlled scientific investigation. Researchers must possess appropriate institutional approval and follow established laboratory safety protocols when handling this compound. This product is restricted to qualified research facilities and is not suitable for clinical trials, dietary supplementation, or any form of human administration.
